LivaNova
(Nasdaq: LIVN)
announced today that it appointed J. Christopher Barry as a new board director.
Barry’s appointment becomes effective today and he joins the board’s Audit and Compliance Committee. In turn, Andrea Saia intends to retire from the board on Dec. 31, 2023. Saia initially joined the board of the London-based medtech company as a director in 2016.
With the changes, the LivaNova board will include 10 directors until Saia’s retirement at the end of the year.
“The LivaNova board of directors is pleased to welcome Chris Barry,” said Bill Kozy, interim CEO and chair of LivaNova. “Chris has spent his career in the medical technology industry, and we look forward to adding his commercial expertise and ability to drive long-term growth to the board. Additionally, on behalf of the entire board, I’d like to thank Andrea for her many contributions, notably her ability to offer frequent insights on talent, share marketing expertise and her overall positivity brought clear value to our board.”
Barry brings more than two decades of experience in the medical technology industry. He most recently served as CEO and director at NuVasive from 2018 until its merger with Globus Medical, completed last month.
Prior to NuVasive, Barry served as SVP and president of surgical innovations for Medtronic from January 2015 to October 2018. Before that, he spent 15 years in various sales and leadership roles at Covidien, which Medtronic eventually acquired.
“I am honored to join the LivaNova board of directors and look forward to supporting the efforts to bring life-changing improvements to patients around the world, while maximizing value to the shareholders,” said Barry.